TRAX (First Tracks Biotherapeutics, Inc. Ordinary Shares)

Insider Trading Activity

Every open-market purchase and sale reported by TRAX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

Form 4 Filings
40
most recent
Open-Market Buys
0
code P
Sales
1
code S
Reporting Insiders
9
current holders
TRAX — Recent Form 4 Transactions (latest 2026-09-04)
FiledInsiderRole TypeSharesValue
2026-09-04 J. Anthony Ware Director MIXED
2026-08-18 BENJAMIN STONE Chief Business Officer A
2026-08-18 Daniel Faga President, CEO A
2026-08-18 Paul F. Lizzul Chief Medical Officer A
2026-08-05 Daniel Faga President, CEO A
2026-08-05 Paul F. Lizzul Chief Medical Officer A
2026-08-05 BENJAMIN STONE Chief Business Officer A
2026-06-17 John P. Schmid Director M
2026-06-17 Rita Jain Director M
2026-06-17 DENNIS M FENTON Director M
2026-06-17 John A Orwin Director M
2026-06-17 J. Anthony Ware Director M
2026-06-17 Magda Marquet Director M
2026-06-12 Rita Jain Director A
2026-06-12 Magda Marquet Director A
2026-06-12 John P. Schmid Director A
2026-06-12 John A Orwin Director A
2026-06-12 DENNIS M FENTON Director A
2026-06-12 J. Anthony Ware Director A
2026-05-14 DENNIS M FENTON Director A
2026-05-14 Ajim Tamboli Chief Financial Officer A
2026-05-14 J. Anthony Ware Director A
2026-05-14 John P. Schmid Director A
2026-05-14 Magda Marquet Director A
2026-05-14 Paul F. Lizzul Chief Medical Officer A
2026-05-14 BENJAMIN STONE Chief Business Officer A
2026-05-14 John A Orwin Director A
2026-05-14 Rita Jain Director A
2026-05-14 Daniel Faga President, CEO A
2026-04-23 Ajim Tamboli Chief Financial Officer A
2026-04-22 EcoR1 Capital, LLC 10%+ Owner Sell
2026-04-22 ANAPTYSBIO, INC 10%+ Owner J
2026-04-22 John A Orwin Director A
2026-04-22 DENNIS M FENTON Director A
2026-04-22 Daniel Faga President, CEO A
2026-04-22 Magda Marquet Director A
2026-04-22 Rita Jain Director A
2026-04-22 John P. Schmid Director A
2026-04-22 Paul F. Lizzul Chief Medical Officer A
2026-04-22 J. Anthony Ware Director A
TRAX — Current Insider Holders
InsiderRole Shares HeldValue
10%+ Owner 3,174,519
President, CEO 496,684
Chief Medical Officer 42,669
Director 37,652
Director 19,194
Director 16,695
Director 15,960
Director 15,660
Director 10,995
How to read Form 4 activity

Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.

Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.

Full filing history and per-insider positions are on the TRAX quote page; the site-wide leaderboard is on the insider transactions hub.